ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Other Events

Item8.01

On May2, 2017, ZIOPHARM Oncology, Inc., or the Company, issued a
press release announcing that an investigator-initiated
Investigational New Drug application to the U.S. Food and Drug
Administration for a Phase 1 trial infusing the Companys
CD33-specific CAR T therapy for relapsed or refractory acute
myeloid leukemia is now active, with the first patient to be
enrolled in the study expected to begin treatment in the third
quarter of 2017.

A copy of the above referenced press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

2

About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Recent Trading Information

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed its last trading session up +0.06 at 7.10 with 755,042 shares trading hands.